US 12,447,184 B1
Lactic acid bacteria and use thereof
Dong-Hyun Kim, Seoul (KR); and Myung Joo Han, Seoul (KR)
Assigned to University-Industry Cooperation Group of Kyung Hee University, Gyeonggi-do (KR); and NAVIPHARM CO., LTD., Gyeonggi-do (KR)
Appl. No. 16/614,242
Filed by UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, Gyeonggi-do (KR); and NAVIPHARM CO. LTD, Gyeonggi-do (KR)
PCT Filed Sep. 28, 2018, PCT No. PCT/KR2018/011607
§ 371(c)(1), (2) Date Nov. 15, 2019,
PCT Pub. No. WO2019/066599, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 10-2017-0127422 (KR), filed on Sep. 29, 2017.
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61K 35/745 (2015.01); C12N 1/20 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A61K 35/745 (2013.01); C12N 1/205 (2021.05)] 8 Claims
 
1. A method for treating a mental disorder or an inflammatory disease, comprising: administering a pharmaceutical composition comprising Lactobacillus reuteri NK33 (KCCM12090P) into a subject,
wherein the inflammatory disease is colitis, and
wherein the mental disorder is one or more selected from the group consist of anxiety, depression, and stress.